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Abstract   1 
Plasmodium falciparum is a protozoan parasite that causes the most severe form of human 2 
malaria. Four other Plasmodium species can also infect humans – P. vivax, P. ovale, P. 3 
malariae and P. knowlesi – but P. falciparum is the most prevalent Plasmodium species in 4 
the African region, where 90% of all malaria occurs, and it is this species that causes the 5 
great majority of malaria deaths.  These were reported at 438,000 in 2015 (1) from an 6 
estimated 214 million cases; importantly, however, figures for the global burden of malaria 7 
tend to have wide margins of error due to poor and inaccurate reporting (2-4).  In this 8 
Perspective, the unique features of the P. falciparum parasite are highlighted and current 9 
issues surrounding the control and treatment of this major human pathogen are discussed. 10 
What is special about Plasmodium falciparum?   11 
All Plasmodium parasites share unique and fascinating biological features, enabling them to 12 
invade, colonise, replicate and persist in diverse host environments.  They have a complex 13 
and highly-evolved lifecycle that requires both an insect vector and a vertebrate host (fig 1A), 14 
and their cell and molecular biology is highly unusual.  Plasmodium belongs to an early-15 
diverging lineage of eukaryotes, the Apicomplexan phylum, which evolved from a free-living 16 
algal ancestor into an obligate intracellular parasite (5): the resultant cells carry a relic plastid 17 
(6) as well as other special organelles that facilitate invasion of host cells (7) (fig 1B).  Inside 18 
these cells they grow via various syncytial modes of cell division rather than conventional 19 
binary fission (8).  Plasmodium parasites are widespread throughout the animal kingdom but 20 
tend to be highly specialised for particular hosts – avian, reptilian, mammalian, etc.: P. 21 
falciparum infects only humans and great apes (9, 10), and although its basic biology shares 22 
all the above characteristics, it also has additional features that can cause unique and 23 
severe pathology in humans.  The case fatality rate of falciparum malaria is ~0.3-0.45%, but 24 
in a subset of severe malaria cases it can exceed 20% (11) (table 1).   25 
 26 
Table 1: Manifestations of severe falciparum malaria 27 
 28 
Clinical manifestation Frequency Prognostic of poor outcome? Linked laboratory indices 
  Children Adults Children Adults   
Cerebral coma or impaired 
consciousness 
+++ ++ +++ +++ Parasite sequestration in brain 
Repeated convulsions +++ + + ++ 
Parasite sequestration in brain, 
Hypoglycaemia 
Prostration +++ +++ + + 
 
Respiratory distress +++ ++ +++ +++ Metabolic acidosis/Hyperlactataemia, 
     
Severe anaemia 
Pregnancy malaria - +++ - +++ 
Parasite sequestration in placenta, 
Hypoglycaemia 
 29 
Table shows a non-exhaustive list of key disease features in severe falciparum malaria. 30 
Adapted from data in references (4) and (11).  31 
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 Firstly, in the human-pathogenic stage of its lifecycle, which consists of growth inside 32 
erythrocytes (fig 1A), P. falciparum can infect erythrocytes of all ages.  This distinguishes it 33 
from the other major human malaria species, P. vivax, which is restricted to rare immature 34 
erythrocytes called reticulocytes.  Accordingly, whereas P. vivax growth is limited by the 35 
scarcity of reticulocytes, P. falciparum can swiftly reach parasitaemias of 10-20%, and each 36 
infected cell can produce ~20-30 new parasites every 48 hours.  This capacity to reach very 37 
high parasitaemias exacerbates malaria pathologies such as severe anaemia, metabolic 38 
acidosis and respiratory distress (11, 12) (table 1).   39 
 Secondly, P. falciparum has a family of major virulence genes called var genes which 40 
are unique to this parasite and its close relatives (ape malaria parasites in the ‘Laverania’ 41 
subgenus (13)).  These virulence factors play key roles in other lethal pathologies, such as 42 
cerebral malaria and pregnancy malaria (14) (table 1).  Var genes encode an adhesive 43 
protein, ‘PfEMP1’, which is exported and expressed on the surface of infected erythrocytes, 44 
allowing the cells to be sequestered in capillaries as they mature. Thus they avoid clearance 45 
by the spleen, but sequestered cells obstruct blood flow and cause inflammatory responses 46 
that are particularly harmful in vessels of the brain or placenta (15).  Most other malaria 47 
parasites do not adhere in this way and do not cause cerebral comas or pregnancy 48 
complications.  Furthermore, the var gene family is variantly expressed, giving rise to 49 
antigenic variation in PfEMP1, and hence immune evasion (16), which is one reason why 50 
sterile immunity to falciparum malaria is rarely achieved in humans. 51 
 A third unusual feature of P. falciparum is its extremely biased genome, the 52 
implications of which are not yet understood.  At 81% A/T, this is one of the most biased 53 
genomes ever sequenced (17).  Not all human malaria parasites share this bias  – the P. 54 
vivax genome is only ~58% A/T – and although elegant studies have recently elucidated 55 
how the bias is maintained at a molecular level (18), they have not established why.  It may 56 
be that A/T-rich DNA favours permissive transcription (19) or rapid DNA replication (20, 21) 57 
– both signature features of P. falciparum.  Certainly, this genome bias presents a severe 58 
challenge to biologists in sequencing, cloning, expressing and working with P. falciparum 59 
genes. 60 
Current issues in P. falciparum biology 61 
Hot topics in P. falciparum biology range from the molecular to the epidemiological.  On the 62 
molecular and cellular level, the parasite has unusual basic biology that is both academically 63 
interesting and medically important.  Understanding the parasite’s unique features will help 64 
scientists to focus on new targets for antimalarial drugs and vaccines.  These features 65 
include the unusual genome mentioned above; the unusual cell cycles (8)(fig 1A); the 66 
biochemical specialisations for an intracellular lifecycle (22); and the invasion pathways (7), 67 
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transport pathways (23) and capacities for host-cell remodelling (24, 25) that have evolved to 68 
facilitate life inside anucleate erythrocytes.  Interestingly, a recent screen for genes that are 69 
essential for growth in the rodent malaria parasite P. berghei revealed an unprecedentedly 70 
high proportion of indispensable genes, which was extrapolated to be similarly true for P. 71 
falciparum (26).  This raises conceptual questions about reductive specialisation for an 72 
intracellular parasitic lifestyle and importantly it also raises the prospect of an abundance of 73 
genetically-essential targets for antimalarial drugs.    74 
 Moving to the epidemiological level, falciparum malaria has historically been a major 75 
scourge of humans throughout the tropics and subtropics, and attempts to control the 76 
disease have a long and complex history.  Excitingly and controversially, the prospect of 77 
global malaria eradication has recently returned to the fore (27), after the failure of the first in 78 
‘WHO Global Malaria Eradication Programme’ in the mid-20th century.  The original 79 
programme was built upon considerable success in eliminating the disease from Europe and 80 
North America in the early 1900s via large-scale environmental insecticide treatment which 81 
targeted the mosquito vector, together with drug treatment of malaria cases in humans.  82 
Reasons for its ultimate failure included the development of mosquito resistance to the 83 
insecticide DDT and parasite resistance to the antimalarial chloroquine, as well as the more 84 
challenging dynamics of disease transmission in hyperendemic tropical areas.  Figure 1C 85 
illustrates the subsequent rebound in the global burden of malaria.  Encouragingly, however, 86 
more modern interventions have reduced this burden once again, with a drop of ~40% in 87 
malaria in Africa over the past 15 years, attributed primarily to the use of insecticide-treated 88 
bednets (28, 29).   89 
 Whether or not malaria can actually be eradicated with current tools remains a topic 90 
of debate (30, 31), and some of these tools are now increasingly threatened, as discussed 91 
below.  There is a clear historical trend for disease resurgence when control measures fail or 92 
when funding to sustain them fails (not only malaria (fig 1C) but other parasitic diseases 93 
such as sleeping sickness have illustrated this (32)).  Nevertheless, striking successes have 94 
already been achieved in eliminating malaria from island nations such as Sri Lanka (33), as 95 
well as non-island nations on the margins of transmission zones, such as Morocco and 96 
Kyrgyzstan.  Others including China and Malaysia, benefitting from regional cross-border 97 
collaboration, are close to the elimination goal (34). 98 
Current challenges in P. falciparum biology 99 
Key challenges in the P. falciparum field range from basic science to real-world intervention.  100 
At the level of basic science, the unusual biology of this parasite makes it challenging to 101 
work with, although it remains one of only two human malaria parasites that can be grown in 102 
laboratory culture at all (35) (the other is the zoonotic macaque parasite P. knowlesi (36)).  103 
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The ability to culture P. falciparum in human erythrocytes makes genetic experiments 104 
feasible (37), albeit painfully inefficient when compared to model systems.  Nevertheless, in 105 
the past decade great advances have been made in developing genetic tools for gene 106 
tagging, gene knockouts, knockdowns, inducible approaches and gene editing (38), and the 107 
scope for further improvement remains substantial.  Collaborative efforts to sequence 108 
hundreds of P. falciparum strains from around the world are fast revealing the genetic 109 
diversity of the species (39), but challenges remain in efficiently adapting field strains to in 110 
vitro culture (40) and there are persistent concerns about the relevance of laboratory 111 
experiments conducted exclusively in strains that have been in culture for decades.   112 
 Meanwhile, major challenges persist for P. falciparum control in the real world.  Drug 113 
resistant parasites (as well as insecticide-resistant mosquito vectors) are a recurring 114 
problem, as are sufficiently accurate and sensitive diagnostics, while the gold-standard 115 
disease-prevention tool of a vaccine against P. falciparum remains elusive despite decades 116 
of scientific effort.   117 
 P. falciparum parasites have historically developed resistance to every antimalarial 118 
deployed (fig 1C).  Current first-line treatments are all based on artemisinin derivatives, 119 
which are highly effective but very short-lived in the bloodstream.  Therefore they are always 120 
supplied with a second longer-lasting antimalarial as a combination therapy or ’ACT’.  121 
Resistance to ACTs is now found in much of the greater Mekong region (41, 42).  As yet, 122 
there is no strong evidence that resistance has spread from Asia to Africa, where it would be 123 
particularly devastating, but this has previously happened with antimalarials such as 124 
chloroquine and antifolates, and the ever-increasing global movement of people makes the 125 
transport of resistant parasites very likely.  The current picture is complicated by the unusual 126 
nature of artemisinin resistance: a phenotype of ‘delayed parasite clearance’ in which 127 
parasites are cleared only slowly from the blood, and may go ’dormant’ to survive the brief 128 
period of drug exposure before recrudescing (41, 43).  This phenotype is difficult to measure 129 
in vitro, its genetic basis is only partially understood (44, 45), and it may be dependent on 130 
the genetic background of the parasite, perhaps explaining why it has developed in Asian 131 
but not yet in African strains (46, 47).  As highlighted below, it will be imperative to preserve 132 
the effectiveness of the ACT antimalarials for as long as possible.  133 
 Developing an effective vaccine remains a huge challenge owing to the parasite’s 134 
antigenic complexity, antigenic redundancy and capacity for antigenic variation (48).  In 135 
2018, the first ever vaccine for falciparum malaria, Mosquirix™, will begin to be supplied in 136 
three African countries, Ghana, Kenya and Malawi, supported by the WHO ‘Malaria Vaccine 137 
Implementation Programme’.  However, this programme remains exploratory and the 138 
vaccine is unlikely to be a game-changer in global malaria control because it does not offer 139 
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sterile or long-term protection.  Mosquirix™ features an epitope from the invading 140 
‘sporozoite’ stage of the parasite (fig 1A), and thus targets the pre-erythrocytic parasite 141 
stages in order to stimulate an immune response pre-empting symptomatic blood-stage 142 
malaria.  Unfortunately, Phase-3 clinical trials revealed that the vaccine offered only ~30% 143 
protection, waning rapidly over a four-year period (49).  Deployment in young children across 144 
Africa might still prevent millions of severe malaria episodes and deaths, but this must be 145 
weighed against concerns about cost, uptake, impact on other malaria control interventions, 146 
and the potential risk of shifting severe disease to older age groups (50).   147 
 Finally, in order to prevent malaria transmission it is vital to detect and then treat P. 148 
falciparum infections accurately, even when asymptomatic, because they may nevertheless 149 
still be transmitted by mosquitoes (51).  People who have been repeatedly exposed tend to 150 
develop functional – albeit non-sterile – immunity to the parasite, suppressing infections to a 151 
level that causes few symptoms.  These can be difficult to detect (because asymptomatic 152 
people do not seek treatment) and if the parasitaemia is very low they can also be difficult to 153 
diagnose without sensitive PCR-based tests or expert microscopy.  Field diagnosis is often 154 
limited to antibody-based ‘rapid diagnostic tests’ (52), which frequently have lower 155 
sensitivity. 156 
Future perspectives on P. falciparum 157 
Arguably the most urgent current issue in the P. falciparum field is the threat now posed by 158 
artemisinin-resistant parasites.  The community must work to understand the underlying 159 
biology of resistance, develop and deploy the right assays for it in the field – genetic, 160 
phenotypic or a combination of both – and thus track its spread across the malaria-endemic 161 
world.  Retrospective studies have traced the emergence and spread of chloroquine 162 
resistance in the mid-1900s (53), but for the first time we now have the capacity to do this in 163 
real time, putting in place proactive interventions.  Indeed, the genetic basis of artemisinin 164 
resistance was at least partially elucidated almost as it emerged, via a massive multicentre 165 
effort to sequence parasites and perform genome-wide association studies (44).  It may be 166 
possible to prevent, or at least impede, the spread or de novo emergence of artemisinin-167 
resistant parasites in Africa via in-depth surveillance, preventing the use of artemisinin 168 
monotherapy and using the right partner drugs in ACTs (since partner drugs are also at risk 169 
of resistance, invalidating the ACT approach (54)).  170 
 In parallel with this effort, since artemisinin will inevitably be lost sooner or later as an 171 
effective first-line drug, it is crucial to develop new drugs with different modes of action, and 172 
to improve their transit through the drug development pipeline (55).  Product Development 173 
Partnerships such as the Medicines for Malaria Venture (MMV) are key players here.    174 
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 Finally, returning to the eradication agenda, there are strong advocates for an 175 
audacious plan which was backed by the WHO in 2015 to halt the spread of artemisinin 176 
resistance by entirely eliminating P. falciparum from the Mekong region, where resistant 177 
parasites currently reside (56).  This would probably require the unprecedented use of mass 178 
drug administration in complete populations – a logistical and ethical challenge – but the 179 
concept merits serious consideration if the WHO target of reducing malaria cases and 180 
deaths by 90% by 2030 is to be met.  If successful, it could set a template for other regional 181 
elimination programmes.   182 
 P. falciparum is a fascinating and sophisticated parasite that has co-evolved with 183 
humans for thousands of years, shaping human genetics (57) and remaining a major public 184 
health problem to this day.  There has never been a better moment for a concerted effort at 185 
the elimination, and eventually the global eradication, of this parasite. 186 
 187 
Summary points 188 
 Plasmodium falciparum is responsible for most of the global burden of death from 189 
malaria – approximately half a million per annum. 190 
 The P. falciparum parasite is an early-diverging eukaryote with many unusual and 191 
interesting biological features. 192 
 Studying this parasite in the laboratory is challenging but great advances have been 193 
made in recent decades. 194 
 Control of falciparum malaria has improved greatly in the past 15 years but is 195 
threatened by the repeated emergence of drug resistant parasites.  196 
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Figure legend 354 
Fig. 1: P. falciparum lifecycle, parasite structure and disease-control timeline  355 
A) Schematic showing the lifecycle of P. falciparum.  Approximate parasite numbers shown 356 
at each stage highlight the severe bottlenecks and massive expansions at various stages.  357 
In the mosquito vector the sexual cycle occurs: pre-gametes called gametocytes are 358 
taken up in a blood meal from an infected human; these mature into gametes, mate and 359 
form a motile zygote called an ookinete which crosses the gut wall and encysts to form an 360 
oocyst.  In the oocyst, asexual replication occurs and sporozoites are released to migrate 361 
to the salivary glands, whence they are injected into another human host during a 362 
mosquito bite.  Sporozoites migrate from the bite site to the liver, where they multiply 363 
asexually inside hepatocytes over a period of ~7 days and then release merozoites which 364 
infect erythrocytes.  In erythrocytes, 48-hour cycles of asexual replication, cell lysis and 365 
reinvasion occur, causing all the symptoms of malaria.  A small subset of these parasites 366 
differentiates into gametocytes ready for mosquito transmission.   367 
B) Structure and organelles of P. falciparum.  The apical complex that facilitates host cell 368 
invasion includes rhoptries, micronemes and dense granules, all containing proteins that 369 
are released during host cell invasion.  The merozoite surface is densely coated with 370 
proteins that aid host cell attachment and are cleaved and shed during invasion.  The two 371 
endosymbiont-derived organelles, mitochondrion and plastid, are also shown. 372 
C) Timeline showing malaria control interventions and the global burden of malaria deaths 373 
from 1990 to 2015 (+/- 95% confidence intervals).  Data are from the Global Burden of 374 
Disease study (58), which records data from 1990 onwards; comparable global data prior 375 
to 1990 are lacking.  376 
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